Entrada Therapeutics (TRDA) Gains from Investment Securities (2020 - 2026)
Entrada Therapeutics (TRDA) recorded quarterly Gains from Investment Securities of $20000.0 in Q1 2026, up 121.51% quarter-over-quarter from -$93000.0 in Q4 2025, and up 144.44% on a YoY basis from $8181.8 in Q1 2025.
Entrada Therapeutics (TRDA) Gains from Investment Securities (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Gains from Investment Securities history runs 7 years deep, the most recent figure standing at $20000.0 for Q1 2026.
- In Q1 2026, Gains from Investment Securities rose 144.44% year-over-year to $20000.0; the TTM figure through Mar 2026 stood at -$149000.0 (down 103.24% YoY), while the FY2025 annual figure was -$214000.0, down 104.63% from the prior year.
- Gains from Investment Securities was $20000.0 for Q1 2026 at Entrada Therapeutics, up from -$93000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $68.3 million in Q3 2023 to a low of -$2.0 million in Q2 2024.
- Historically, Gains from Investment Securities has averaged $5.9 million across 5 years, with a median of -$14500.0 in 2024.
- The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities jumped 1436.12% in 2023, then tumbled 3500.0% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at -$562000.0 in 2022, then jumped by 12248.22% to $68.3 million in 2023, then slumped by 90.24% to $6.7 million in 2024, then plunged by 101.4% to -$93000.0 in 2025, then surged by 121.51% to $20000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $20000.0 (Q1 2026), -$93000.0 (Q4 2025), and -$36000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Entrada Therapeutics | 295.36 Mn | 295.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20,000.00 |
| Mar 31, 2026 | 20,000.00 |
| Dec 31, 2025 | -93,000.00 |
| Dec 31, 2025 | -93,000.00 |
| Sep 30, 2025 | -36,000.00 |
| Sep 30, 2025 | -36,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Jun 30, 2025 | -40,000.00 |
| Mar 31, 2025 | -45,000.00 |
| Mar 31, 2025 | -45,000.00 |
| Dec 31, 2024 | 6.67 Mn |
| Dec 31, 2024 | 6.67 Mn |
| Sep 30, 2024 | -1,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -2.02 Mn |
| Jun 30, 2024 | -2.02 Mn |
| Mar 31, 2024 | -28,000.00 |
| Mar 31, 2024 | -28,000.00 |
| Sep 30, 2023 | 68.27 Mn |
| Sep 30, 2023 | 68.27 Mn |